Objectives: To determine whether family physicians provide different ambulatory care to patients with health insurance from managed care organization (MCO) versus fee-for-service (FFS) plans.

Study Design: Multimethod cross-sectional observational study.

Patients And Methods: A total of 4454 patients made office visits to 138 family physicians in northeastern Ohio. Direct observation with the Davis Observation Code and a structured checklist were used to assess the process of care. Patient satisfaction was measured with the Medical Outcomes Study 9-Item Visit Rating Form.

Results: Among 1588 patients with MCO insurance and 876 with FFS insurance, no differences were noted in the number of visits per year, length of visits, percentage of visits for well care, or the percentage of visits in which medicines were prescribed in analyses controlling for patient mix. Visits by patients with MCO insurance were more likely to involve referrals to another physician than visits by patients with FFS insurance. Patient satisfaction and time use during visits were comparable for the 2 groups.

Conclusions: Managed care insurance appears to increase involvement of the primary care provider in the referral process. However, in a healthcare market with moderate managed care penetration in which the same physicians see patients with different types of insurance, the process of care is affected little by type of insurance coverage.

Download full-text PDF

Source

Publication Analysis

Top Keywords

managed care
16
care
9
insurance
9
family physicians
8
visits
8
process care
8
patient satisfaction
8
patients mco
8
mco insurance
8
ffs insurance
8

Similar Publications

Abdominal ectopic pregnancy is a rare type of ectopic pregnancy associated with high maternal and perinatal mortality. We present a case of a 28-year-old now primipara who was misdiagnosed to have abruptio placentae and ruptured uterus on two different occasions from a primary health care center but was found to have an advanced abdominal ectopic gestation at 21 weeks gestational age. The patient was managed by exploratory laparotomy and is currently doing well.

View Article and Find Full Text PDF

Background: The prevalence of gestational diabetes mellitus (GDM) is dependent on the diagnostic criteria used and there is no consensus on screening methods and diagnostic criteria. The International Association for Diabetes in Pregnancy Study Group (IADPSG) recently put forward new diagnostic criteria and encourages its adoption worldwide. The aim of this study was to determine the incidence of GDM and to compare the foeto-maternal outcomes of women diagnosed with GDM in the Federal Medical Centre, Yenagoa using the WHO 1999 and IADPSG criteria.

View Article and Find Full Text PDF

Objective: Primary care offers an entry point into the health care system for adolescents experiencing mental illnesses. This study explored the perceptions of adolescents with an anxiety or mood disorder accessing primary care for mental health services.

Methods: Qualitative interpretive descriptive design was employed.

View Article and Find Full Text PDF

Triangular Margin: Reliable Imaging Feature of Fibrous Dysplasia in Long Bones?

J Comput Assist Tomogr

January 2025

Department of Radiology, Division of Musculoskeletal Imaging and Intervention, Massachusetts General Hospital, Boston, MA.

Objective: To determine the utility of a triangular margin as an imaging diagnostic feature for fibrous dysplasia.

Materials And Methods: We retrospectively reviewed all surgically biopsied or managed benign and malignant bone tumors by a single orthopedic oncologist over 19 years (2003 to 2022). A musculoskeletal radiologist and an orthopedic oncologist, both with >10 years of experience, retrospectively evaluated all imaging in consensus.

View Article and Find Full Text PDF

Tarlatamab is a bispecific T-cell engager immunotherapy targeting delta-like ligand 3 (DLL3) and the cluster of differentiation 3 (CD3) molecule. In the phase 2 DeLLphi-301 trial of tarlatamab for patients with previously treated small cell lung cancer, tarlatamab 10 mg every 2 weeks achieved durable responses and encouraging survival outcomes. Analyses of updated safety data from the DeLLphi-301 trial demonstrated that the most common treatment-emergent adverse events were cytokine release syndrome (53%), pyrexia (38%), decreased appetite (36%), dysgeusia (32%), and an emia (30%).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!